JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

BACKGROUND: Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor of JAK1 and JAK2. This study tested the efficacy of baricitinib versus placebo on albuminuria in adults with Type 2 diabetes at hig...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nephrol Dial Transplant
Main Authors: Tuttle, Katherine R, Brosius, Frank C, Adler, Sharon G, Kretzler, Matthias, Mehta, Ravindra L, Tumlin, James A, Tanaka, Yoshiya, Haneda, Masakazu, Liu, Jiajun, Silk, Maria E, Cardillo, Tracy E, Duffin, Kevin L, Haas, Joseph V, Macias, William L, Nunes, Fabio P, Janes, Jonathan M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
ORIGINAL ARTICLES
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6212720/
https://ncbi.nlm.nih.gov/pubmed/29481660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfx377
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados